Hormonal
Type 2 diabetes mellitus impairs weight reduction in obese patients primarily through energy conservation (reduced glucosuria), hyperinsulinemia-driven lipid storage, and the use of obesogenic anti-diabetes medications.
If you have Type 2 Diabetes and struggle to lose weight, it is likely not just a willpower issue. Your body is conserving energy because your blood sugar is better controlled (less sugar peed out), and medications like insulin or sulfonylureas may be actively promoting fat storage. Discuss switching to diabetes medications that support weight loss (such as GLP-1 agonists or SGLT2 inhibitors) with your doctor, as these can help overcome these physiological barriers.
Among patients with increased body fat, the mechanisms underlying impaired weight reduction for those with type 2 diabetes mellitus are multifactorial, and include energy conservation (i.e., improved glucose control and reduced glucosuria), hyperinsulinemia (commonly found in many patients with type 2 diabetes mellitus), potential use of obesogenic anti-diabetes medications, and contributions from multiple body systems.
Why this rating
This is a narrative review summarizing multiple mechanisms; it cites observational data and clinical trials but does not present new primary experimental data itself.
Source
Why does type 2 diabetes mellitus impair weight reduction in patients with obesity? A review
Harold Bays · Obesity Pillars · 2023
DOI 10.1016/j.obpill.2023.100076
More from this paper
- Improvement in glycemic control in T2D patients leads to energy conservation via reduced glucosuria and osmotic water weight loss, which mechanically impedes scale-based weight reduction.Moderate
- Obesogenic anti-diabetes medications, specifically those that increase insulin exposure (insulin, sulfonylureas, meglitinides), actively promote weight gain and hypoglycemia, which necessitates increased caloric intake and impairs weight loss.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →